Voloridge Investment Management
IBRX icon

Voloridge Investment Management’s ImmunityBio IBRX Stock Holding History

Voloridge Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Sell
1,721,902
-1,205,650
-41% -$9.13M 0.06% 346
2026
Q1 		$22.5M Buy
+2,927,552
New +$20M 0.09% 313
2021
Q4 		– Sell
-100,022
Closed -$974K – 1689
2021
Q3 		$974K Buy
100,022
+39,853
+66% +$439K 0.01% 1292
2021
Q2 		$859K Buy
+60,169
New +$994K 0.01% 1307

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Voloridge Investment Management's IBRX Position: Q2 2026 in Review

Voloridge Investment Management reduced its ImmunityBio (IBRX) stake by 41% in Q2 2026, selling an estimated $9.13M and leaving 1,721,902 shares worth $15.1M. The position accounts for 0.06% of the portfolio, ranked #346.

Voloridge Investment Management first reported a position in IBRX in Q2 2021 and has held it in 4 quarters since. The position peaked at $22.5M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Voloridge Investment Management held 1,721,902 shares of ImmunityBio worth $15.1M as of Q2 2026.
  • Voloridge Investment Management sold 1,205,650 ImmunityBio shares in Q2 2026, an estimated $9.13M.
  • ImmunityBio made up 0.06% of Voloridge Investment Management's portfolio in Q2 2026, its #346 holding.
  • Voloridge Investment Management first reported a position in ImmunityBio in Q2 2021 and has held it in 4 quarters since.
  • Voloridge Investment Management's ImmunityBio position peaked at $22.5M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.